Understanding T cell responses to predict cancer treatment outcomes
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
This study is looking at how your immune system's T cells react to cancer and normal cells to see if those reactions can help predict how well you'll respond to treatments for advanced cancers like lung and bladder cancer, while also keeping an eye on any side effects you might experience.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10910903 on NIH RePORTER |
What this research studies
This research investigates how T cell responses to tumor and self-antigens can predict patient responses to immune checkpoint therapy, which is used to treat advanced cancers like lung and bladder cancer. By analyzing T cell characteristics before and after treatment, the study aims to identify biomarkers that indicate both the effectiveness of the therapy and the likelihood of experiencing adverse immune-related events. Patients will be monitored over time to assess changes in their T cell populations, utilizing advanced techniques such as single-cell RNA sequencing to gain insights into their immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with advanced lung or bladder cancer who are considering or currently undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with cancers not treated by immune checkpoint inhibitors or those who are not eligible for such therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized cancer treatments by identifying which patients are likely to benefit from immune checkpoint inhibitors and minimizing the risk of adverse effects.
How similar studies have performed: Previous research has shown promise in identifying biomarkers related to immune responses in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- Benaroya Research Inst at Virginia Mason — Seattle, United States (Active)
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.